Patients on a combination of Abraxane and gemcitabine, another chemotherapy, lived for a median 8.5 months, compared to 6.7 months for those that received gemcitabine alone.

Celgene’s Abraxane, in combination with chemotherapy, helped patients with advanced pancreatic cancer live about two months longer than those given chemotherapy alone, a study found.

Dec. 8, 2003 (San Antonio) — Abraxane (formerly ABI-007) is an old drug in a new package that promises to make chemotherapy less toxic and more effective for women with metastatic breast cancer ...

Abraxane sales accounted for around 8% of the company's net product sales in 2012. In the second quarter of 2013, Abraxane sales totaled $155 million, up 41% on a year-over-year basis.

Patients taking Abraxane with the chemotherapy gemcitabine survived a median of 8.5 months, compared with 6.7 months for those only on the single drug, Summit, New Jersey-based Celgene said ...

Abraxane was granted a Priority Review designation by the FDA in May 2013. For more information call (908) 673-9000 or visit Abraxane.com. Related News.

Abraxane has been on the market for the treatment of metastatic breast cancer since 2005, and as of October 2012 is also available in the U.S. for advanced or metastatic non-small cell lung cancer ...

phase III trial of Abraxane in pancreatic cancer will be a statistical success, my research predicts. The trickier question is whether or not the Abraxane survival benefit observed in the trial ...

Pomalyst and Abraxane are the next largest revenue generators for Celgene (CELG) after Revlimid. Their revenue growth is critical for Celgene to achieve revenues of $20 billion by 2020.